

**Supplemental Table 1: Description of diagnoses of iRMD patients with and without Autoinflammatory diseases**

	n (%)
<b>Autoinflammatory diseases (n=117)</b>	
Juvenile-onset systemic still disease	5/117 (4.3)
Unclassified Autoinflammatory disease	15/117 (12.8)
Behçet disease	21/117 (17.9)
Still disease	9/117 (7.7)
Monogenic autoinflammatory disease	67/117 (57.3)
FMF	64/67
CAPS	3/67
<b>Non- Autoinflammatory diseases (n=1545)</b>	
Giant Cell arteritis	37/1545 (2.4)
Takayasu disease	5/1545 (0.3)
	30/1545 (1.9)
Systemic juvenile idiopathic arthritis	
	15/1545 (1.0)
Other	
Other inflammatory rheumatism	19/1545 (1.2)
Other spondylarthritis	30/1545 (1.9)
Other vasculitis	21/1545 (1.4)
Chondrocalcinosis	1/1545 (0.1)
Undifferentiated connectivite	5/1545 (0.3)
Mixed connectivite tissus disease	11/1545 (0.7)
Goit	2/1545 (0.1)
Uveitis	3/1545 (0.2)
Systemic erythematous lupus	118/1545 (7.6)
IGG4 related disease	4/1545 (0.3)
Myositis	22/1545 (1.4)
Myositis inclusion body	1/1545 (0.1)
Chronic recurrent multifocal osteomyelitis	2/1545 (0.1)
Rheumatoid arthritis	509/1545 (32.9)
Pseudorhizomelic arthritis	35/1545 (2.3)

Psoriatic rheumatism	165/1545 (10.7)
Sarcoidosis	21/1545 (1.4)
Systemic sclerosis	64/1545 (4.1)
Spondylarthritis	344/1545 (22.3)
Sjogren syndrome	43/1545 (2.8)
Antiphospholipid syndrome	5/1545 (0.3)
ANCA vasculitis	33/1545 (2.1)

**Supplemental table 2: Cases reports of pediatric patients**

<b>Number of patients</b>	<b>17</b>
<b>Median age</b>	<b>12 [3-16]</b>
<b>Autoinflammatory diseases</b>	
Familial Mediterranean fever	7 (41%)
PFAPA	2
Cryopyrin associated periodic syndrom	2
DADA2	1
Unclassified autoinflammatory disease	2
SJIA	3
<b>Daily treatment for SAID</b>	
Colchicine	7 (41%)
Adalimumab	2
Canakinumab	1
Anakinra	3
Tocilizumab	1
<b>Outcome</b>	
Benin form	17 (100%)